Trial Profile
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTC-867 Administered Orally to Healthy Subjects.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs HTC 867 (Primary)
- Indications Psychotic disorders
- Focus Adverse reactions
- 02 Sep 2009 Planned end date changed from 1 Jun 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
- 02 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Apr 2009 Additional location identified as reported by ClinicalTrials.gov.